Latest Health News

Metrics Real Estate Multi-Strategy Fund has announced an estimated ordinary dividend of AUD 0.0096 per security, with key dates set for late January and early February 2025. The dividend is unfranked and relates to the financial period ending January 31, 2025.

Supply Network Limited projects a solid half-year profit of $19.8 million and announces a fully franked interim dividend of 32.0 cents per share, signaling steady financial health ahead of its full results.

Global Masters Fund Limited's latest quarterly report confirms compliance with all financial obligations and highlights a recent interest rate increase on its convertible notes, supported by a robust loan-to-value ratio.

ECP Emerging Growth Limited has reported steady financial health and full compliance with its convertible notes obligations for the quarter ended December 2024, maintaining a conservative loan-to-value ratio and an unchanged conversion price.

Volt Resources Limited has successfully repaid a AU$500,000 loan to RiverFort Global Opportunities, underscoring its financial discipline amid ongoing graphite project developments.

Respiri Limited reports a standout December quarter marked by a 67% surge in patient program enrolments and robust revenue growth, bolstered by strategic acquisition synergies from Orb Health. The company is poised for further expansion in 2025 amid promising contract negotiations and evolving US healthcare reimbursement policies.

4DMedical has signed a landmark commercial agreement with Qscan Radiology Clinics, marking its first Australian contract to integrate both Pulmonary Function and Pulmonary Structure imaging products.

Biotron Limited has engaged US-based C14 Consulting Group to drive strategic partnerships for its antiviral drug portfolio, including lead candidate BIT225, while advancing its Hepatitis B research.

Paradigm Biopharmaceuticals has secured a $6.3 million R&D Tax Incentive refund, lifting its cash reserves to $31 million and reinforcing its push into Phase 3 osteoarthritis clinical trials.

SomnoMed Limited reported a solid cash flow performance for Q4 2024, with operating activities generating a net inflow of $1.525 million and ending the quarter with $18.5 million in cash reserves.

SomnoMed reports a robust 19.8% revenue increase in Q2 FY25 and updates its full-year guidance, reflecting strong demand and operational improvements amid ongoing production enhancements.

Biome Australia Limited has expanded its distribution footprint to over 6,000 health retail and practitioner locations, marking a 20% increase in six months and advancing toward its Vision 27 target of 8,000 sites by FY27.